Stockscreener 앱 받기
4.04
0.50%
0.02
시간 외 거래:
4.03
-0.010
-0.25%
전일 마감가:
$4.02
열려 있는:
$4.02
하루 거래량:
969.09K
Relative Volume:
2.04
시가총액:
$282.04M
수익:
$63.39M
순이익/손실:
$-219.51M
주가수익비율:
-1.2772
EPS:
-3.1631
순현금흐름:
$-231.83M
1주 성능:
+0.25%
1개월 성능:
-9.21%
6개월 성능:
-41.87%
1년 성능:
-47.12%
1일 변동 폭
$4.02
$4.235
1주일 범위
$3.95
$4.24
52주 변동 폭
$3.95
$9.1592
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
명칭
Bicycle Therapeutics Plc Adr
전화
011441223261503
주소
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
4.04 | 289.72M | 63.39M | -219.51M | -231.83M | -3.1631 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Hold |
| 2025-10-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-08 | 개시 | Stephens | Equal-Weight |
| 2024-09-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-07 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | 개시 | Cowen | Outperform |
| 2022-07-28 | 개시 | Barclays | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-04-13 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-02-14 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | SVB Leerink | Outperform |
| 2021-12-09 | 개시 | Needham | Buy |
| 2021-09-30 | 개시 | B. Riley Securities | Buy |
| 2021-04-20 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-06-12 | 개시 | Oppenheimer | Outperform |
| 2020-04-17 | 개시 | H.C. Wainwright | Buy |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-09-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-06-17 | 개시 | Canaccord Genuity | Buy |
| 2019-06-17 | 개시 | Goldman | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
| 2019-06-17 | 개시 | Piper Jaffray | Overweight |
모두보기
Bicycle Therapeutics Plc Adr 주식(BCYC)의 최신 뉴스
Bicycle Therapeutics’ SWOT analysis: stock navigates trial delays - Investing.com
After plunging 20.2% in 4 weeks, here's why the trend might reverse for Bicycle Therapeutics (BCYC) - MSN
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Sees Significant Increase in Short Interest - MarketBeat
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - ChartMill
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bicycle Therapeutics (BCYC) loses 19.0% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bicycle Therapeutics (BCYC) schedules 2026 AGM with director, pay and auditor votes - Stock Titan
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
Bicycle Therapeutics doses first patient in pancreatic cancer trial By Investing.com - Investing.com South Africa
Bicycle Therapeutics doses first patient in pancreatic cancer trial - Investing.com
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares of Stock - MarketBeat
Bicycle Therapeutics plc (BCYC) stock price, news, quote and history - Yahoo Finance UK
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Bicycle Therapeutics (BCYC) proxy: June 17 AGM, board and pay votes (BCYC) - Stock Titan
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC) - Yahoo Finance
Bicycle Therapeutics (BCYC) Drops 19.0% Over the Past 4 Weeks, Reasons a Potential Turnaround Could Be Near - Bitget
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) Given New $15.00 Price Target at Needham & Company LLC - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Given New $36.00 Price Target at Oppenheimer - Defense World
Bicycle Therapeutics stock price target lowered to $7 by RBC Capital - Investing.com South Africa
Citizens cuts Bicycle Therapeutics stock price target on strategic shift By Investing.com - Investing.com South Africa
Bicycle Therapeutics (BCYC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Truist cuts Bicycle Therapeutics stock price target on pipeline shift By Investing.com - Investing.com South Africa
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift By Investing.com - Investing.com India
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift - Investing.com
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
SUNation Energy Inc. (NASDAQ:SUNE) Short Interest Update - Defense World
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Merit Medical Systems, Inc. (NASDAQ:MMSI) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Principal Financial Group Inc. Grows Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 2.6%Time to Sell? - MarketBeat
Bicycle Therapeutics announces leadership changes for next phase By Investing.com - Investing.com South Africa
Bicycle Therapeutics announces leadership changes for next phase - Investing.com
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline - ChartMill
Bicycle Therapeutics Plc Adr (BCYC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bicycle Therapeutics Plc Adr 주식 (BCYC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Apr 06 '26 |
Sale |
5.05 |
251 |
1,268 |
96,136 |
| Thompson Travis Alvin | Chief Financial Officer |
Apr 02 '26 |
Sale |
4.91 |
799 |
3,923 |
65,466 |
| Thompson Travis Alvin | Chief Financial Officer |
Apr 06 '26 |
Sale |
5.05 |
102 |
515 |
65,364 |
| Perry Jennifer Scott | Chief Operating Officer |
Apr 02 '26 |
Sale |
4.91 |
1,038 |
5,097 |
92,834 |
| Perry Jennifer Scott | Chief Operating Officer |
Apr 06 '26 |
Sale |
5.04 |
370 |
1,865 |
92,464 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Apr 02 '26 |
Sale |
4.91 |
5,967 |
29,298 |
613,029 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Apr 06 '26 |
Sale |
5.05 |
1,716 |
8,666 |
611,313 |
| Skynner Michael | CHIEF SCIENTIFIC OFFICER |
Apr 02 '26 |
Sale |
4.91 |
1,879 |
9,226 |
160,087 |
| Skynner Michael | CHIEF SCIENTIFIC OFFICER |
Apr 06 '26 |
Sale |
5.05 |
525 |
2,651 |
159,562 |
2.60%
0.94%
자본화:
|
볼륨(24시간):